This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Genetics

Diabetes and cardiovascular risk in UK South Asians: an overview

September 2018 Br J Cardiol 2018;25(suppl 2):S8–S13 doi:10.5837/bjc.2018.s08

Diabetes and cardiovascular risk in UK South Asians: an overview

Wasim Hanif, Radhika Susarla

Abstract

Introduction Type 2 diabetes (T2D) is a global epidemic with changing demographics that poses a huge challenge for the health and economy of all nations and ethnicities. Ethnicity is defined in terms of a culture of people in a given geographic region, including their language, heritage, religion and customs.1 South Asians constitute about 1.6 billion people from the countries of the Indian subcontinent, this includes Afghanistan, Bangladesh, Bhutan, India, Maldives, Pakistan, Nepal and Sri Lanka.2 Over 37 million ethnic South Asian diaspora live across every continent.3 Prevalence of diabetes in South Asians According to the International D

| Full text
News from the American Heart Association Scientific Sessions 2013

February 2014 Br J Cardiol 2014;21:10–11 Online First

News from the American Heart Association Scientific Sessions 2013

BJCardio Staff

Abstract

ENGAGE AF-TIMI 48: success for edoxaban in AF The new factor Xa inhibitor, edoxaban (Daiichi-Sankyo), was as effective in preventing strokes and safer than warfarin in patients with atrial fibrillation (AF) in the ENGAGE AF-TIMI 48 trial. The ENGAGE AF-TIMI 48 (Effective AnticoaGulation with Factor XA Next Generation in Atrial Fibrillation – Thrombolysis In Myocardial Infarction 48) trial included more than 21,000 AF patients from 46 countries who were randomised to edoxaban at one of two doses (60 mg or 30 mg per day) or warfarin. Results (table 1) showed that both edoxaban doses were associated with significantly less major bleeding than

| Full text

February 2012 Br J Cardiol 2012;19:16

Care for the individual patient

Abstract

Bureaucracy The mortality rate for heart failure remains unchanged with 11.6% of heart failure (HF) admissions dying as inpatients, and 33% mortality at around one year, according to the most recent data from the National Heart Failure Audit.  This was presented to the meeting by Professor Theresa McDonagh (King’s College Hospital, London). Data collection continues to improve with 85% of NHS trusts submitting data over the preceding 12 month period, she said.  Access to cardiology services was associated with improved outcomes and a higher usage of evidence-based therapy and subsequent access to outpatient HF services. The likely challen

| Full text

September 2008 Br J Cardiol 2008;15:237-39

CVD risk and beyond at H·E·A·R·T UK conference 2008

BJC editorial team

Abstract

Risk calculation Dr Peter Brindle, the Research and Development Director and GP at the Bristol Primary Care Trust, lit the spark by taking the first lecture spot. With the title Advances and Controversies in CVD Risk Estimation he was stepping into the lions’ den. Earlier in the year H·E·A·R·T UK welcomed the continued use of well-established and validated risk calculation tools within the National Institute of Health and Clinical Excellence (NICE) lipid modification guideline and had endorsed the guideline group’s decision not to recommend more novel experimental approaches. So the delegates were keen to hear Dr Brindle announce the

| Full text

November 2002 Br J Cardiol 2002;9:572-5

The genetics of cardiovascular disorders

John Payne, Hugh Montgomery

Abstract

No content available

| Full text

September 2002 Br J Cardiol 2002;9:449-59

Hypertrophic cardiomyopathy: from gene to bedside

Sami Firoozi, Julia Rahman, William J McKenna

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now